Does amifostine have a role in chemoradiation treatment?

被引：68

作者：

Brizel, DM

机构：

来源：

LANCET ONCOLOGY | 2003年 / 4卷 / 06期

关键词：

D O I：

10.1016/S1470-2045(03)01132-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：378 / 381

页数：4

共 29 条

[1] Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy [J].

Andreassen, CN ;

Gran, C ;

Lindegaard, JC .

SEMINARS IN RADIATION ONCOLOGY, 2003, 13 (01) :62-72

[2] A phase II trial of subcutaneous Amifostine and radiation therapy in patients with head and neck cancer [J].

Anné, PR ;

Curran, WJ .

SEMINARS IN RADIATION ONCOLOGY, 2002, 12 (01) :18-19

[3] Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer [J].

Antonadou, D ;

Pepelassi, M ;

Synodinou, M ;

Puglisi, M ;

Throuvalas, N .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 52 (03) :739-747

[4] Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer [J].

Antonadou, D ;

Coliarakis, N ;

Synodinou, M ;

Athanassiou, H ;

Kouveli, A ;

Verigos, C ;

Georgakopoulos, G ;

Panoussaki, K ;

Karageorgis, P ;

Throuvalas, N .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (04) :915-922

[5] A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma [J].

Bourhis, J ;

De Crevoisier, R ;

Abdulkarim, B ;

Deutsch, E ;

Lusinchi, A ;

Luboinski, B ;

Wibault, P ;

Eschwege, F .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (05) :1105-1108

[6] Phase III randomized trial of amifostine as a radioprotector in head and neck cancer [J].

Brizel, DM ;

Wasserman, TH ;

Henke, M ;

Strnad, V ;

Rudat, V ;

Monnier, A ;

Eschwege, F ;

Zhang, J ;

Russell, L ;

Oster, W ;

Sauer, R .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) :3339-3345

[7] Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01) [J].

Cooper, JS ;

Guo, MD ;

Herskovic, A ;

Macdonald, JS ;

Martenson, JA ;

Al-Sarraf, M ;

Byhardt, R ;

Russell, AH ;

Beitler, JJ ;

Spencer, S ;

Asbell, SO ;

Graham, MV ;

Leichman, LL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1623-1627

[8] REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].

CRAWFORD, J ;

OZER, H ;

STOLLER, R ;

JOHNSON, D ;

LYMAN, G ;

TABBARA, I ;

KRIS, M ;

GROUS, J ;

PICOZZI, V ;

RAUSCH, G ;

SMITH, R ;

GRADISHAR, W ;

YAHANDA, A ;

VINCENT, M ;

STEWART, M ;

GLASPY, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :164-170

[9] IS THE OUTLOOK GREY FOR WR-2721 AS A CLINICAL RADIOPROTECTOR [J].

DENEKAMP, J ;

STEWART, FA ;

ROJAS, A .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1983, 9 (08) :1247-1249

[10] A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003 [J].

Fu, KK ;

Pajak, TF ;

Trotti, A ;

Jones, CU ;

Spencer, SA ;

Phillips, TL ;

Garden, AS ;

Ridge, JA ;

Cooper, JS ;

Ang, KK .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (01) :7-16

← 1 2 3 →